Ellagic Acid hydrate

Catalog No.S5516 Batch:S551601

Technical Data

Formula	C₁₄H₆O₈.H₂O
Molecular Weight	320.21	CAS No.	314041-08-2
Solubility (25°C)*	In vitro	DMSO	2 mg/mL (6.24 mM)


* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Ellagic acid is a potent inhibitor of protein kinase CK2 with IC50s of 0.04, 2.9 and 3.5 μM for CK2, Lyn and PKA respectively. It shows potent antioxidant, anti-mutagenic and antidepressant properties.

Targets

CK2 ^[1] (Cell-free assay)	Lyn ^[1] (Cell-free assay)	PKA ^[1] (Cell-free assay)
0.04 μM	2.9 μM	3.5 μM

In vitro

Ellagic acid (EA) is able to inhibit the growth of several cancer cells. EA inhibited cell proliferation in a dose- and time-dependent manner by arresting both cell lines at the G1 phase of the cell cycle, which were from elevating p53 and Cip1/p21 and decreasing cyclin D1 and E levels. EA also induced caspase-3-mediated apoptosis by increasing the Bax : Bcl-2 ratio and restored anoikis in ES-2 and PA-1 cells. It is well known to have a free radical scavenging activity^[1]. EA reversed epithelial to mesenchymal transition by up-regulating E-cadherin and down-regulating Vimentin^[2].

In vivo

A 90-day subchronic toxicity study further demonstrated that orally feeding EA (9.4, 19.1, 39.1 g/kg b.w., resp.) could not induce mortality or treatment-related clinical signs throughout the experimental period on F344 rats, indicating the low toxicity of EA to mammalians. Furthermore, EA exhibits potent anticancer and anticarcinogenesis activities towards breast, colorectal, oral, prostate, pancreatic, bladder, neuroblastoma, melanoma, and lymphoma cells^[1]. Treatment of PANC-1 xenografted mice with EA resulted in significant inhibition in tumor growth and prolong mice survival rate^[2].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines Ovarian carcinoma ES-2 and PA-1 cells Concentrations 10~100 μM Incubation Time 12, 24, 48 h Method Ovarian carcinoma cell lines were plated at 100,000 cells in six-well tissue culture dishes. After 18 h of culture, cells were treated with different concentrations of DMSO-dissolved EA (0, 10, 25, 50, 75, or 100 μM) or chemotherapeutic drugs (doxorubicin, paraplatin, and paclitaxel) or a combination of both drugs. At the various time points, cells were collected by trypsinization and stained with trypan blue, and the cell number in suspension was counted in duplicate using a hemocytometer.
Animal Study:^{^[2]}	Animal Models PANC-1 xenografts (Balb C nude mice, 4-6 weeks old) Dosages 0, 10 mg/kg, 20 mg/kg and 40 mg/kg Administration oral gavage

Cell Assay:^{^[1]}

Cell lines
Ovarian carcinoma ES-2 and PA-1 cells
Concentrations
10~100 μM
Incubation Time
12, 24, 48 h
Method
Ovarian carcinoma cell lines were plated at 100,000 cells in six-well tissue culture dishes. After 18 h of culture, cells were treated with different concentrations of DMSO-dissolved EA (0, 10, 25, 50, 75, or 100 μM) or chemotherapeutic drugs (doxorubicin, paraplatin, and paclitaxel) or a combination of both drugs. At the various time points, cells were collected by trypsinization and stained with trypan blue, and the cell number in suspension was counted in duplicate using a hemocytometer.

Animal Study:^{^[2]}

Animal Models
PANC-1 xenografts (Balb C nude mice, 4-6 weeks old)
Dosages
0, 10 mg/kg, 20 mg/kg and 40 mg/kg
Administration
oral gavage

References

Selleck's Ellagic Acid hydrate has been cited by 1 publication

Non-catalytic allostery in α-TAT1 by a phospho-switch drives dynamic microtubule acetylation [ J Cell Biol, 2022, 221-11e202202100]	PubMed: 36222836

Non-catalytic allostery in α-TAT1 by a phospho-switch drives dynamic microtubule acetylation [ J Cell Biol, 2022, 221-11e202202100]

PubMed: 36222836

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.